BG Medicine, Inc. (BGMD)

Market Cap	545,969
Revenue (ttm)	1.57M
Net Income (ttm)	-6.96M
Shares Out	11.37M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,795
Open	0.0111
Previous Close	0.0200
Day's Range	0.0218 - 0.0218
52-Week Range	0.0101 - 0.1900
Beta	0.78
Analysts	n/a
Price Target	1.40 (+6,322.0%)
Est. Earnings Date	n/a

About BGMD

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and is...

• Industry: Life Sciences Tools & Services
• IPO Date: Feb 4, 2011
• CEO: Paul Sohmer
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: BGMD

Full Company Profile

Financial Performance

In 2015, BG Medicine's revenue was $1.57 million, a decrease of -43.81% compared to the previous year's $2.79 million. Losses were -$5.30 million, -34.24% less than in 2014.

Financial Statements

News

There is no news available yet.